API | sodium chromate cr-51

sodium chromate cr-51 (chromitope sodium) Report issue

Small molecule Imaging Approved ^FDA

ChEMBL Drug Central Drugs@FDA MeSH PubChem

Active Ingredient History

NOW

Chromate ion CR-51 is a radioactive chromium 51 in the form of sterile, nonpyrogenic aqueous solution of sodium chromate. It is a diagnostic radiopharmaceutical for intravenous administration. This agent provides Chromium 51 decays by electron capture and gamma emission with a physical half-life of 27.7 days. It is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss. No adverse reactions specifically attributable to Chromate ion CR-51 injection have been reported. ^NCATS

Chemistry

SMILES: [O-][51Cr]([O-])(=O)=O
InChIKey: ZCDOYSPFYFSLEW-HONVGLGOSA-N
Mol. Mass: 114.9424
ALogP: Missing data
ChEMBL Molecules:

albumin, chromated cr 51 serum

sodium chromate cr 51

More Chemistry

Pharmacology

Mechanism of Action:
- Hemoglobin subunit alpha (Homo sapiens) ^UniProt
Multi-specific: Missing data
Imaging: 51-chromium
Black Box: No
Availability: Discontinued
Delivery Methods: Parenteral
Pro Drug: No

Organizations (2)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (3)

Anemia, Hemolytic (approved 1971)

Polycythemia (approved 1971)

Spherocytosis, Hereditary (approved 1971)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue